Asset
SETMELANOTIDE
Rhythm Pharmaceuticals Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01867437 | phase1 | completed | 2013-05-01 | 2014-03-01 | Rhythm Pharmaceuticals, Inc. | Effects of RM-493 on Energy Expenditure in Obese Individuals |
| NCT02431442 | phase1 | completed | 2012-01-01 | 2014-01-01 | Rhythm Pharmaceuticals, Inc. | Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RM-493 Administered to Healthy, Obese, Non-diabetic Volunteers |
FDA applications (0)
This company has no applications containing this asset.